Death risk is low if prostate cancer hasn't progressed in 10 years

Most biochemical recurrence of prostate cancer following radical prostatectomy occurs within 10 years, and patients who remain free from progression a decade postoperatively can be counseled that their risk of subsequent cancer-related morbidity and mortality is low.

Related Videos

Related Content

Advertisement

July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke

The level II code A9616 will be effective starting on October 1, 2025.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.

Related Content

Advertisement

July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke

The level II code A9616 will be effective starting on October 1, 2025.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.